- Home
- KYN vs MYGN Comparison
KYN vs MYGN Comparison
Compare KYN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYN
- MYGN
- Stock Information
- Founded
- KYN 2004
- MYGN 1991
- Country
- KYN United States
- MYGN United States
- Employees
- KYN N/A
- MYGN N/A
- Industry
- KYN Finance/Investors Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KYN Finance
- MYGN Health Care
- Exchange
- KYN Nasdaq
- MYGN Nasdaq
- Market Cap
- KYN 2.1B
- MYGN 642.0M
- IPO Year
- KYN N/A
- MYGN 1995
- Fundamental
- Price
- KYN $12.20
- MYGN $7.24
- Analyst Decision
- KYN
- MYGN Hold
- Analyst Count
- KYN 0
- MYGN 13
- Target Price
- KYN N/A
- MYGN $13.50
- AVG Volume (30 Days)
- KYN 561.5K
- MYGN 1.4M
- Earning Date
- KYN 01-01-0001
- MYGN 11-06-2025
- Dividend Yield
- KYN 8.99%
- MYGN N/A
- EPS Growth
- KYN N/A
- MYGN N/A
- EPS
- KYN 0.71
- MYGN N/A
- Revenue
- KYN N/A
- MYGN $832,900,000.00
- Revenue This Year
- KYN N/A
- MYGN $0.17
- Revenue Next Year
- KYN N/A
- MYGN $6.19
- P/E Ratio
- KYN $13.79
- MYGN N/A
- Revenue Growth
- KYN N/A
- MYGN 3.83
- 52 Week Low
- KYN $7.84
- MYGN $3.76
- 52 Week High
- KYN $9.88
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- KYN 45.51
- MYGN 65.47
- Support Level
- KYN $12.10
- MYGN $6.73
- Resistance Level
- KYN $12.33
- MYGN $7.05
- Average True Range (ATR)
- KYN 0.18
- MYGN 0.40
- MACD
- KYN -0.02
- MYGN 0.07
- Stochastic Oscillator
- KYN 17.54
- MYGN 72.28
About KYN Kayne Anderson Energy Infrastructure Fund Inc.
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.